All In Biotech

Drug Trial Radar · NCT04967664

Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery

An Interventional, Phase III, Double-blind, Randomized, Controlled, Parallel-group, Multi-site, Clinical Trial Evaluating the Efficacy and Safety of Qutenza® in Subjects With Post-surgical Neuropathic Pain

Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 412 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

412

Actual

Start

Jul 13, 2021

Primary completion

Aug 28, 2025

Study completion Aug 28, 2025

Sponsor

Lead sponsor
Averitas Pharma, Inc.Industry
Sponsor type
Industry
First posted
Jul 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an interventional, Phase III, double-blind, randomized, controlled, parallel-group, multi-site, clinical trial to confirm the efficacy and safety of repeated topical application of Qutenza (capsaicin 8% topical system) versus low-dose capsaicin control (capsaicin 0.04% topical system) in subjects with moderate to severe postsurgical neuropathic pain (PSNP).

Conditions

  • Post Surgical Neuropathic Pain

Interventions

  • Qutenza (capsaicin) 8% topical systemDrug

    High concentration capsaicin

  • capsaicin 0.04% topical systemDrug

    Low-dose capsaicin control

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the 24-Hour Average Pain Intensity (API) Between Week 2 and Week 12 [Core Phase]Time frame: From the Baseline Phase (Day -7 to Day -1) to Visit 6 (Week 12/Day 84).
  2. Change From Baseline in the 24-Hour API to Week 12 [Core Phase]Time frame: From the Baseline Phase (Day -7 to Day -1) to Visit 6 (Week 12/Day 84).

Locations

64 sites in 6 countries. Site status is shown where the registry gives one.

  • Tucson Orthopaedic Institute

    Tucson, Arizona

  • ILD Research Center

    Vista, California

  • International Spine, Pain, and Performance Center

    Washington D.C., District of Columbia

  • South Lake Pain Institute

    Clermont, Florida

  • University Clinical Research - DeLand Clinical Research Unit

    DeLand, Florida

  • Florida Research Center, Inc.

    Miami, Florida

  • Clinical Research of West Florida

    Tampa, Florida

  • Drug Studies America

    Marietta, Georgia

  • Rush University Medical Center

    Chicago, Illinois

  • Neuroscience Research Center, LLC

    Overland Park, Kansas

  • Kansas City Bone & Joint Clinic, P.A.

    Overland Park, Kansas

  • Boston Clinical Trials

    Boston, Massachusetts

  • Great Lakes Research Group, Inc.

    Bay City, Michigan

  • Premier Pain Centers

    Shrewsbury, New Jersey

  • Ainsworth Institute of Pain Management

    New York, New York

  • Accellacare

    Wilmington, North Carolina

  • The Center for Clinical Research

    Winston-Salem, North Carolina

  • META Medical Research Institute, LLC

    Dayton, Ohio

  • Main Line Spine

    King of Prussia, Pennsylvania

  • New Phase Research & Development

    Knoxville, Tennessee

  • Expert Pain

    Houston, Texas

  • The University of Texas Health Science Center at San Antonio

    San Antonio, Texas

  • Wasatch Clinical Research, LLC

    Salt Lake City, Utah

  • CHU Amiens Picardie

    Amiens, France

  • Centre Regional De Lutte Contre Le Cancer (Crlcc) -Centre Paul Papin

    Angers, France

  • Centre Hospitalier Jean Rougier

    Cahors, France

  • Centre Hospitalier Universitaire de Clermont Ferrand

    Clermont-Ferrand, France

  • Centre Hospitalier Regional Universitaire (CHRU) de Lille - Hopital Claude Huriez

    Lille, France

  • Clinique Francois Chenieux

    Limoges, France

  • Cochin Hospital-Paris Descartes University

    Paris, France

  • Groupe Hospitalier Paris saint-Joseph

    Paris, France

  • CHU Poitiers / La Miletrie

    Poitiers, France

  • Centre Hospitalier Departemental Vendee - Centre d'evaluation et de Traitement de la Douleur

    La Roche-sur-Yon, Pays de la Loire Region, France

  • CHU de Nantes - Hopital Nord Laennec

    Nantes, Pays de la Loire Region, France

  • VUMC

    Amsterdam, Netherlands

  • PT&R

    Beek, Netherlands

  • NOCEPTA

    Hengelo, Netherlands

  • Leiden University Medical Center (LUMC)

    Leiden, Netherlands

  • Vitamed Nzoz Im. Edyty Jakubow

    Bialystok, Poland

  • Nzoz Neuro-Medic

    Katowice, Poland

Showing 40 of 64 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.